Abstract: . . .  is not discussed in this chapter. Chapter 13 was dedicated to thrombophilia. I wonder why it was included at the end of the book and not among the first 5 Chapters. I also wonder why Ian Jennings omits to discuss whether the decrease of fibrinolysis is (or not) a potential thrombotic risk factor. Importantly, a chapter on thrombosis in children was incorporated in this book and finally, a chapter on new drugs for anticoagulant therapy, which could be called "the after coumadin/heparin era", was also included with updated information on the pentasacharides fonda- parinux and idraparinux, on drugs affecting factor VII activity, direct Factor Xa and . . .
. . .  community peer reviewed and published immediately upon acceptance cited in PubMed and archived on PubMed Central yours you keep the copyright Submit your manuscript here: http://www.biomedcentral.com/info/publishing_adv.asp Bio Med central Thrombosis Journal 2005, 3 :7 http://www.thrombosisjournal.com/content/3/1/7 Page 2 of 2 (page number not for citation purposes) in the diagnostic as well as in the treatment of deep venous thrombosis in pregnant women. The antithrom- botic treatment in women with recurrent miscarriage and thrombophilia which is conflictive and still unresolved is not discussed . . .
--1435,2,359,1604,7177